文献速递皮肤肿瘤

免疫缺陷状态可能影响蕈样肉芽肿的结局与免疫检查点分子表达

Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study.
PubMed 文献 · J Am Acad Dermatol · 2017-11-10

本研究为单中心病例对照研究,评估免疫缺陷(ID)对蕈样肉芽肿(MF)的影响。结果显示,合并ID的MF患者治疗失败更多、血管中心性更常见、细胞更大,且PD1和PDL1表达更高;生存率、FOXP3和IL-17表达无差异。提示ID与MF不良结局及免疫检查点分子表达升高相关。

要点

  • 合并免疫缺陷的MF患者治疗失败风险更高。
  • 免疫缺陷与MF中PD1和PDL1表达升高相关。
  • 此类患者可能适合免疫检查点抑制剂治疗,需进一步研究。

核心结论

  • 免疫缺陷与蕈样肉芽肿患者更差的治疗结局及更高的PD1和PDL1表达相关。
  • 合并免疫缺陷的蕈样肉芽肿患者可能成为免疫检查点抑制剂治疗的候选者,有待进一步研究。

研究设计与样本

  • 病例对照研究,比较17例合并免疫缺陷的MF患者与年龄、分期、种族匹配的对照。
  • 作为比较分析的一部分,纳入23例合并免疫缺陷的MF患者(既往淋巴瘤、近期/当前妊娠、HIV、低丙种球蛋白血症、既往化疗)与无免疫缺陷患者。
  • 对12例免疫缺陷患者和10例对照进行PD1、PDL1、FOXP3和IL-17免疫组化检测。

临床怎么用

  • 对合并免疫缺陷的MF患者应警惕更高的治疗失败风险。
  • 此类患者可考虑检测PD1和PDL1表达,评估免疫检查点抑制剂治疗的潜力。

局限性

  • 小样本单中心研究,免疫缺陷类型异质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunodeficiency (ID) correlates with worse outcomes and decreased immune checkpoint molecule expression in melanoma. The impact of ID in mycosis fungoides (MF) is unknown. OBJECTIVE: Our goal was to evaluate the impact of ID in MF. METHODS: We conducted a case-control study of 17 patients with MF and ID versus age-, stage-, and race-matched controls as a subset of a comparative analysis of 23 patients with MF with ID (prior lymphoma, recent/current pregnancy, HIV, hypogammaglobulinemia, and prior chemotherapy) versus without ID. Programmed cell death 1 (PD1), programmed death ligand 1 (PDL1), forkhead box p3, and interleukin 17 immunohistochemistry was performed on 12 patients with ID and 10 controls. RESULTS: Patients with ID had more treatment failure (14 of 23 vs 5 of 17 [P = .028]), more treatment failure within 3 years of diagnosis (12 of 23 vs 4 of 17 [P = .050]), more angiocentrism (6 of 12 vs 0 of 10 [P = .005]), larger cells (1.92 ± 0.51 out of 3 vs 1.30 ± 0.48 out of 3 [P = .009]), more cases with at least 10% PD1 positivity (9 of 11 vs 4 of 10 [P = .031]) and at least 10% PDL1 positivity (7 of 12 vs 2 of 10 [P = .042]), and a higher average percentage of PD1+ cells (43.27 ± 40.22 vs 11.2 ± 13.62 [P = .028]). No differences in survival, forkhead box p3 expression, interleukin 17 expression, histologic depth, ulceration, granulomatous changes, or syringotropism were seen. LIMITATIONS: This was a small single-center study with heterogeneous immunodeficiencies. CONCLUSION: ID correlated with worse outcomes and increased PD1 and PDL1 expression in MF. Patients with MF and ID may be candidates for immune checkpoint inhibitor therapy, pending further investigation.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Warren S, Kheterpal M, Myskowski PL, et al. Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. J Am Acad Dermatol. 2017. PMID: 29132694. doi:10.1016/j.jaad.2017.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。